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 Human Topoisomerase IB (TOP1) and Topoisomerase IIα (TOP2α) are essential 
nuclear enzymes that control DNA topology during DNA replication, gene transcription and 
cell division. These enzymes carry out their catalytic function by making transient single-
strand (type I) or double-strand (type II) breaks in the DNA. In vivo, these complexes are 
short-lived but can be exploited by anti-cancer drugs to mechanistically kill cancer cells. 
Two general classes of compounds can kill cancer cells through a topo-targeted 
mechanism. Interfacial Poisons (IFPs) act at the enzyme-DNA interface to inhibit the 
religation reaction, resulting in the accumulation of DNA double-stand breaks (DSBs) in the 
genomic setting. Catalytic Inhibitor Compounds (CICs) act by interfering with other steps of 
the catalytic cycles such as DNA/protein binding or the cleavage reaction. 
 In this work we identify new Au3+ macrocyclic gold complexes that act as CICs of 
both TOP1 and TOP2α. The complexes exhibit square planar geometry with an aromatic 
system that allows for DNA intercalation with binding affinities in the low micromolar 
range. A cytotoxicity screen across 60 human cancer cell lines performed by the National 
Cancer Institute (NCI, USA) reveals significant anti-tumor potential. Our lead compound 
(butyl gold(III) macrocycle, cmpd 3.) is currently undergoing further studies in animal 
models at the NCI. In vitro assays with purified DNA and enzyme reveal the Au3+ ion to be 
the quintessential switch that allows for DNA intercalation and subsequent inhibition of 
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Chapter 1: Introduction and Background 
Classes of Prokaryotic and Eukaryotic Topoisomerases 
DNA Topoisomerases are ubiquitous nuclear enzymes that control DNA topology 
and are required for cell viability[1]. These enzymes are divided into two major types 
based on the interaction they make with DNA. The type I enzyme is a monomeric unit with 
a single catalytic tyrosine that cleaves one strand of DNA, performs a controlled rotation, 
followed by a re-ligation on the cleaved strand. Type II enzymes require ATP and are 
homodimers containing two catalytic tyrosines. This gives type II the capability of cleaving 
both strands of DNA resulting in a short-lived DNA double-strand break (DSB). The enzyme 
then religates the DSB after passing a distant strand through the break. Thus, type I 
enzymes change the linking number in steps of one, while type II enzymes change the 
linking number in steps of two[2]. Linking number is an integer that reflects the number of 
times one strand of DNA is passed through another. Thus the only way to change the value 
of the linking number is to physically break one (or both) strands of DNA and rejoin them 
after passing another one through the break, which is accomplished by topoisomerases. 
The relaxation and decatentation reactions of TOP1 and TOP2α are shown in (Fig. 1A).  
Both Prokaryotes and Eukaryotes contain Type I and II enzymes. Prokaryotes have a 
further subdivision in the Type II class that contain DNA Gyrase and Topo IV both of which 
are A2B2 heterotetramers[3]. DNA gyrase is found only in prokaryotic systems and contains 
a dual function with the ability to induce supercoils into DNA as well as relax supercoiled 
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DNA. Gyrase is the only topoisomerase known to induce supercoils into DNA rather than 
remove them. This mechanism is ATP-dependent and can therefore change the linking 
number of DNA forward or backward in steps of two. DNA gyrase is a well-validated anti-
bacterial drug target since humans don’t have this protein and it is required for 
prokaryotes to survive[4]. DNA gyrase is reviewed extensively in the literature [5]. 
Eukaryotes, on the other hand, don’t have a type II enzyme to induce supercoils; 
they have acquired a nucleosomal complex of DNA and histone proteins allowing DNA to 
become compact and fit within the nucleus of the cell. In eukaryotes, there are two 
isoforms of type II enzymes denoted TOP2α and TOP2β[2]. Both of these enzymes have 
decatenase activity as well as the ability to unknot DNA, which is a type II-specific 
phenomenon. However, TOP2α is a validated drug-target for cancer chemotherapy, while 
we are still learning more about the specific role of TOP2β[2]. Eukaryotic Type I 
topisomerases are broken down into type IA and type IB with the second being the 
validated drug target. The focus will be on type IB (known as TOP1), as it is the validated 
drug-target for cancer[5]. TOP1 is also the only enzyme in the topoisomerase family known 
to form 3’ phosphotyrosyl linkages with DNA, whereas the rest of the topoisomerases form 
5’ linkages[1]. 
Structure, Function and Catalytic Mechanism of Human Topoisomerase IB (TOP1) 
Human TOP1 is an essential enzyme that acts on the chromatin making single-
strand DNA nicks to relax supercoiled DNA during various genetic events such as DNA 
replication, recombination and transcription [6].  TOP1 is a 98 kDa monomeric unit that 
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begins the catalytic cycle by forming non-covalent interactions with the DNA via H-Bonds 
to direct itself toward the specific enzyme cut-site. This complex molecular recognition unit 
is responsible for locking the enzyme onto the DNA prior to formation of the covalent 
intermediate. Once in correct orientation, the active site tyrosine (Y723) performs a 
nucleophilic attack on the phosphodiester backbone forming a 3’ phosphotyrosyl linkage 
(unique to humans, as prokaryotes form the 5’ linkage). The energy of the supercoil in the 
DNA drives the controlled rotation of the 5’-OH strand around itself, which is the relaxation 
step that ultimately changes the linking number by one. The 5’-OH then performs an 
intramolecular hydrolysis reaction, which is energetically driven by the energy stored in 
the phosphotyrosyl bond. The catalytic cycle ends when the enzyme releases from the DNA, 
allowing enzyme turnover and for a new cycle to begin elsewhere[1, 7, 8]. The generalized 
mechanism for TOP1 mediated relaxation of supercoiled DNA to relaxed DNA is depicted in 
(Fig 1C). 
Structure, Function and Catalytic Mechanism of Topoisomerase II (TOP2α)  
 Human TOP2α and TOP2β are 170 and 180 kDa respectively; both having similar 
structural properties and features. They require Mg2+ and ATP for their catalytic cycle to 
proceed, and they are homodimers containing two key catalytic tyrosine residues (Y805 
and Y821 on the α and β isoform respectively). In the dimerized confirmation TOP2 can sit 
in either an open or closed clamp conformation dependent on ATP binding. The enzyme 
dimer has a preference in binding to DNA “nodes” or crossover regions between segements 
of linked DNA where it selects for a specific alternating purine-pyrimidine sequence. The 
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catalytic cycle begins when TOP2 localizes and bind to the first strand of DNA, known as 
the gating segment (G-segment). Following ATP binding, TOP2 undergoes a conformational 
change to the closed-clamp conformation. Upon binding two Mg2+ cations, an 
ionic/hydrogen bond connection is formed between the phosphodiester backbones, 
allowing the enzyme to cleave both strands four bases apart via nucleophilic attack of the 
tyrosines on the phosphodiester. At this point a DNA-DSB has formed, however this 
“cleavage-complex” is short-lived in cells. The cleavage complex is quickly re-ligated after 
passing the second strand of DNA known as the Transfer segment (T-segment) through the 
break. Following ligation of the G-segment, ATP hydrolysis triggers enzyme turnover with a 
conformational change back to the open-clamp conformation, ready to begin another 
catalytic cycle[9]. The detailed molecular mechanism and catalytic cycle for TOP2α is 



















a) TOP1 and TOP2α both have the ability to relax supercoiled DNA. However, TOP2α has 
decatenase activity, rendering the enzyme capable of unlinking two segments of DNA that 
are interlocked. Whereby TOP2α takes catenated DNA molecules and turns them to 
decatenated DNA molecules. This is accomplished by the ability of TOP2α to make a 
double-strand cut in the DNA and pass a distant segment through the break. [11]. 
b) Shown here is the stepwise catalytic cycle for TOP2α enzymes. The enzyme cycle 
involves binding to a DNA segment (G-segment), performing a controlled cleavage of both 
strands, then passing a distant strand of DNA (T-segment) through the break, followed by 
religation of the G-segment and hydrolysis of ATP for enzyme turnover [11]. 
c) The TOP1-mediated relaxation mechanism is shown in panel C. The monomeric enzyme 
binds to a segment of DNA and cleaves only one strand (through phoosphotyrosine 
linkage), followed by a controlled strand-rotation step. The enzyme then re-ligates the 


















Involvement of TOP1 and TOP2α in various DNA Metabolic Processes 
 TOP1 and TOP2α are common drug targets in the clinical setting, especially in 
cancer chemotherapy[10]. During S phase, DNA replication takes place and with that comes 
a pressing need for TOP1 and TOP2α . As the replication fork proceeds and DNA helicase 
separates the two strands, torque is built up in the helix similar to two telephone cords 
wrapped around each other and pulled apart. This torque generates supercoils ahead and 
behind the replication fork, and it is the job of TOP1 and TOP2α to relax these supercoils so 
the replication machinery can operate in a continuous fashion (Fig 2A). A similar 
phenomenon takes place during transcription, as the transcription machinery separates 
the strands of DNA to read the genetic code. Supercoils are generated ahead of the 
transcription fork similar to the case in DNA replication. It is the job of TOP1 and TOP2α to 
relax these supercoils in the same fashion as before [11]. 
TOP2α plays an important role during mitosis, specifically at the metaphase-
anaphase junction. As the chromosomes line up on the metaphase plate and separate as 
sister chromatids to their respective poles, it is the job of TOP2α to help unlink the 
chromosomes at the centromere[12]. This vital step in mitosis is highly regulated and 
shutting down the job of TOP2α will result in failure of proper chromosomal segregation 
leading to cell death. Also as a result of DNA replication are special structures called 
catenanes. These catenanes are the result of two separate molecules of DNA inter-locked 
within one another with a linking number of one. To separate these two pieces of genetic 
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material we need TOP2α, which can separate the two segments of DNA[2] as shown in (Fig 
2B). 
In conclusion, both TOP1 and TOP2α are at the heart of key events throughout the 
cell cycle, and for cells to replicate their genome and produce proteins requires TOP1 and 
TOP2α. Without them, unfavorable DNA superstructures will form that will ultimately 













Figure 2- Importance of topoisomerase in DNA replication and transcription   
 
a) As DNA replication and transcription proceeds, supercoils are generated in front of the 
replication fork as a result of strand separation induced torque. It is the job of TOP1 and 
TOP2α to relax this DNA, or this will convert to genotoxic lesions upon collision with the 
replication machinery [11]. 
b)A result of replication can be the generation of precatenanes which are solely unlinked 
by TOP2α. These precatenanes, if not decatenated, can be converted to DNA DSBs and 
ultimately result in cell death [11]. 
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Topoisomerase-Targeted Drugs: Distinction between Catalytic Inhibitors and Interfacial Poisons  
 Topoisomerase-targeted drugs act through two general mechanisms; as Catalytic 
Inhibitor Compounds (CICs) and as Interfacial Poisons (IFPs). Most drugs used in the clinic 
are IFPs, and they act by inhibiting the re-ligation step of the enzyme. These agents 
stabilize the “cleavage-complex”, forming a stable ternary complex between enzyme-DNA-
drug. In the genomic context this results in DNA damage that leads to cell death. Poisons 
can be both type I/II specific. Camptothecin (CPT) is an example of a TOP1 IFP and 
Etoposide (VP-16) is an example of TOP2α/β IFP. CPT and VP-16 are both widely 
prescribed in chemotherapy regiments for a plethora of cancers including: breast, colon, 
leukemia and lymphoma[1, 5, 13] 
 Drugs that block any other step within the catalytic cycle of TOP1 or TOP2α are 
referred to as CICs. These compounds are less characterized in the literature, but are of 
great interest in drug design[12, 14]. CICs have the ability to protect cells from poisoning 
by the IFPs and can also kill cancer cells without causing direct DNA damage[15, 16]. These 
CICs can affect the enzyme cycle by either acting with the DNA substrate or the enzyme. A 
common mechanism involves DNA intercalation by a drug that either blocks the enzyme 
cut-site or distorts the DNA substrate. This can alter the molecular recognition unit of the 
enzyme, which makes it unable to lock-on to the DNA to perform a site-specific cleavage 
event[12, 13]. Another route for CICs can be a small molecule that binds tightly to the 
enzyme, blocking its ability to either bind DNA or interfere with the cleavage activity. An 
interesting and well-characterized TOP2α CIC is the family of ICRF compounds 
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(Bisdioxopiperzine), which cross-link the ATPase domains of TOP2 and keep the enzyme in 
a closed-clamp conformation[15]. This inhibits the ATP hydrolysis reaction within the 
catalytic cycle and prevents enzyme turnover, effectively inhibiting future catalytic cycles. 
Again like IFPs, some CICs are type-specific and some are dual inhibitors. An example of a 
CIC that operates in a non-intercalative mechanism is Evodiamine[17]. 
Many anti-cancer agents kill tumor cells through a DNA intercalative mode. This 
pheneomenon of insertion between the nucleotides of DNA unwinds the helix localized to 
the intercalation site[18, 19]. Ellipticine and m-AMSA are both DNA intercalators and 
TOP2α IFPs that utilize their intercalative properties to allow poisoning to occur[20-22]. 
Intercalation does not always result in a poisoning mechanism as is the case with the 
anthracyclines (daunorubicin and adriamycin being most common)[23, 24]. These are flat 
aromatic molecules that intercalate into DNA and add steric bulk to the grooves of DNA. 
This type of molecular mechanism results in a CIC rather than an IFP due to lack of 
hydrogen bonding potential[20]. An overview of CICs and and VP-16 a type II IFP are 












Topo-targeted drugs are classified either as Catalytic Inhibitor Compounds (CICs) or 
Interfacial Poisons (IFPs). CICs can act on all steps of the catalytic cycle, aside from the 
religation reaction. Whe IFPs are specific in that they inhibit the religation reaction, joining 
back the broken segments of DNA. Shown above as an IFP is Etoposide (VP-16), which 
inhibits the religation reaction of the G-segment. The rest of the drugs shown above are 








Metal-Based Drugs in Cancer Chemotherapy 
 Metal-based drugs have a long history in cancer chemotherapeutics with the most 
well-studied and characterized being the platinum-based compound, cisplatin. This simple 
metallo-drug acts in a unique mechanism where it cross-links the strands of DNA by 
binding to guanine residues seven nucleotides from one another on opposing strands[25]. 
The Drug-DNA interaction is stable, and can hold the DNA in such a conformation that puts 
stress on the cell and signals for cell death. This type of interaction along with DNA 
intercalation is known to induce mutations in the DNA[22]. A pitfall of cisplatin has been 
the appearance of resistance to this compound, which is believed to be driven by reduced 
cellular drug-uptake[26]. Moreover, platinum drugs have opened the road to developing 
other metallo-compounds that bind to DNA. Gold(III) exhibits a square planar geometry 
with a higher charge, and is believed to help increase the affinity the negatively charged 
sugar-phosphate backbone of DNA[27, 28]. To date, a number of gold(III) complexes have 
been synthesized and studied, but few mechanistic details are understood regarding these 
gold(III) based drugs[29, 30].  Recently gold polypyridyl complexes have been synthesized 
and are characterized as DNA binders that induce signaling cascades leading to cell cycle 
arrest and apoptosis[31]. Another group has also synthesized a group of cyclometalted 
Au3+ complexes with N-heterocyclic carbene ligands that were first assigned as TOP1 IFPs, 
but then shortly after were shown to act as TOP1 CICs[29]. There is thus a pressing need to 
elucidate the molecular mechanism of these gold-based compounds. 
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Previous Work and Objective 
 The objective of the current work is to evaluate a new class of Bis(Pyrrole-Imine) 
gold(III) macrocycles to see if they target TOP1 and TOP2α. Synthesis of the compounds 
was carried out by the doctoral student, Kate J. Akermann in the laboratory of Dr. Orde 
Munro at the University of KwaZulu-Natal (structures shown in Fig 4). It has been 
previously shown in the laboratory through ethidium-bromide displacement assays, that 
these compounds bind to calf thymus DNA with Ka > 106 M-1 (data not shown). The 
compounds have also been evaluated at the National Cancer Institute (NCI, USA) and show 
significant cytotoxicty against the NCI Panel of 60 cancer cell lines with GI50 (concentration 
of drug that results in 50% growth inhibition) in the low micromolar range (Fig 5A). 
Hierarchal cluster analysis performed by Dr. Munro with the leading gold macrocycle (Fig 
5B, butyl macrocycle, cmpd.3) candidate against 28 FDA-approved cancer drugs with 
known mechanisms of action in the NCI-60 screen clustered the gold macrocycle next to 
CPT (TOP1 IFP).  
 In the following work, we examine the gold(III) macrocycles interaction with DNA in 
vitro using two approaches. Using purified human TOP1 and TOP2α we have measured the 
cleavage reaction of each enzyme through in vitro DNA cleavage assays; to test the 
inhibitory effects of the gold(III) macrocycles towards the TOP1 and TOP2α  enzymes. This 
mechanistic-based approach will elucidate the in vitro molecular mechanism by which 
gold(III) macrocycles kill cancer cells.  
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Figure 4- Structures and common names for gold (III) macrocycles synthesized by 
Kate J. Akermann (Munro Lab) 
 
The gold(III) macrocyclic complexes exhibit square planar geometry with an aromatic 
system and a net positive charge. The compounds were synthesized and shipped in 






Figure 5-Cytotoxicity data for the butyl gold (III) macrocycle (compound 3) and 













*This figure was produced by Dr. Munro and published under his consent. 
a) Cytotoxicity curves of Butyl Complex (compound) against various breast cancer cells in 
the NCI-60 screen. TOP1 IFP (topotecan),CIC (mitoxantrone) and TOP2 CICs (ICRF-187 and 
merbarone) are included as a compare reference for chemotherapeutic agents. 
b) Hierarchal cluster analysis of various FDA-approved anti-cancer agents, clustered by 
their GI50 values which correlate for mechanism of action as described in chapter 2. The 
TOP1 IFP, CPT clustered with compound 3 revealing that there might be a possibility of 





Chapter 2: Materials and Methods 
Expression and Purification of Human Topoisomerase I  
 Human TOP1 was expressed as an N-terminal His-tagged protein in a baculovirus 
system. Experiments were performed with catalytically active wild-type (WT) protein 
kindly provided by TopoGEN. The protein was purified as described by Stewart and 
Champoux[32]. Aliquots of protein were stored in a concentration of [0.3 ug/ul] at 4oC in a 
TOP1 storage buffer (20 mM NaH2PO4 pH 7.4, 300 mM NaCl, 50 ug/ml bovine serum 
albumin, 50% glycerol). One unit of TOP1 will relax approximately 50% of DNA (200 ng of 
input) in 30 minutes at 37oC. Activity of TOP1 is retained for over six months under proper 
temperature and storage conditions. A catalytically inactive Topoismerase IB (Y723F) was 
prepared in which the active site tyrosine was mutated to a phenylalanine. This was kindly 
provided by TopoGEN and expressed in the same manner. 
Expression and Purification of Human Topoisomerase II 
 Human TOP2α was expressed as a 170 kDa dimer in Saccharomyces cerevisiae based 
on the plasmid YEpTOP2PGAL1 following the protocol from[33]. TOP2α was generously 
provided by TopoGEN and stored in a TOP2 storage buffer (10% glycerol, 50 mM Tris-HCl 
pH 7.7, 1 mM PMSF, 2 mM dithiothreitol, 50 ug/ml bovine serum albumin) at -80oC. By 
definition, one unit of TOP2α will decatenate 200 ng of Kinetoplast DNA (kDNA) in 30 
minutes at 37oC. The enzyme can be stored at -80oC and activity can be retained 
indefinitely so long as freeze-thaw cycles are minimized. 
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Expression and Purification of DNA Substrates 
 The catenated DNA substrate, kDNA is a network of interlocked DNA rings 
harvested from the mitochondria of the insect trypanosome Crithidia fasciculate. The kDNA 
in its catenated form is an aggregation of the interlocked DNA maxicircles and minicircles 
(~2.5 kb in monomeric form) is unable to pass through the 1% agarose gel. Upon 
incubation with TOP2α, the minicircles are released as the result of the decatenase activity 
of the enzyme and its ability to make double-strand cuts in the DNA. The mini-circles 
migrate through the 1% agarose gel and allow for visualization of the products within the 
TOP2α catalytic cycle. kDNA is kept in a storage buffer containing (10 mM Tris-HCl pH 7.5 
and 1 mM EDTA). 
 The plasmid pHOT-1 is negatively supercoiled containing a hexadecameric 
sequence, making it an ideal DNA substrate for TOP1 as described by Bonevan et al[34].  
The plasmid itself is a genetically modified PUC12 vector that has the TOP1 high affinity 
cleavage site (5’-TA-3’) inserted into the polylinker region. The pHOT-1 plasmid also 
contains an ampicilin resistance segment. 
Synthesis and Characterization of Gold (III) Macrocycles 
 Kate J. Akermann carried out the synthesis of the gold complexes in the laboratory 
of Dr. Orde Q. Munro at the University of KwaZulu-Natal. A total of seven compounds have 
been synthesized. One of the compounds has a Ni2+ ion as the metal (compound. 7) and one 
is metal free (compound. 6) to serve as controls. The other five all have Au3+ ions as their 
core, with modifications all in the alkyl-bridge portion of the molecule. The derivatives in 
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the bridge are as follow: Propyl (compound 1), Dimethyl (compound 2), Butyl (compound 
3), Chloro (compound 4). The last compound of our library is unique that it contains a 
further modification of compound 1 on the opposite end of the molecule (quinoxoline 
region) where the chemists have added two methyl groups (compound 5). The 
nomenclature and structures of all compounds are summarized in Fig 4. 
DNA Unwinding Assays 
As discussed in chapter 1, DNA intercalation is a common characteristic of many 
anti-cancer drugs. By intercalating between the bases of DNA, there is an unwinding of the 
helix and a change in the twist (Tw), which is a measurement of the number of times one 
strand twists around the other. The Tw is compensated by the writhe (Wr), which is 
described as the deformation of the DNA double helix in a 3-dimensional plane. The Tw and 
Wr sum to form a Linking Number (Lk) (Lk = Tw + Wr), which is a fixed integer that 
describes the number of times one stand is physically linked with the other. Therefore the 
Lk can only be altered by breaking/resealing the DNA (the action of topoismerases), so 
intercalative drugs change the Tw and Wr, but not LK. Thus in the presense of TOP1, the 
changes in tw will be reversed by alterantions in Lk values[35, 36]. This assay allows the 
distinction between drugs that have the ability to intercalate DNA and those that do not. 
DNA unwinding reactions were assembled on ice with 200 ng of supercoiled pHOT-
1 plasmid and incubated with 10U of TOP1 for 30 minutes at 37oC in a final volume of 29 ul 
containing TGS buffer (10 mM Tris-HCl, pH 7.9, 5% glycerol, 0.1 mM Spermidine, 1 mM 
EDTA, 150 mM NaCl, 0.1% bovine serum albumin). After the incubation, supercoiled DNA 
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(form I) was converted to relaxed DNA (form IR). As a positive control, adding SDS to a final 
concentration of 1% and stopping the reaction after 30 minutes was used as a baseline 
control for fully relaxed DNA. After the 30-minute relaxation step, designated control and 
test drugs were added to their specific reaction tubes (final concentration of DMSO = 0.1%) 
and allowed to incubate for another 30 minutes at 37oC. To account for the DMSO in the 
drug solutions, a solvent control (DMSO at final concentration of 0.1%) was used to rule out 
DMSO effects. Reactions were stopped with sodium dodecyl sulfate (SDS) (final 
concentration. of 1%) and treated with proteinase K (PK) (final concentration of 50 μg/ml) 
for 30 minutes at 37oC. Following digestion, DNA loading dye was added (0.017 % 
bromophenol blue, 0.017% xylene cyanofol, 6.67% glycerol) and a phenol-choloroform 
extraction was performed. An equal volume of Phenol:Chloroform:Isoamyl (PCI) alcohol 
(25:24:1 w/v) was added and samples were vortexed briefly (10 seconds) and spun for 5 
min at 13,000 RPM. The upper phase (aqueous layer) was transferred to a new tube and 33 
ng of DNA was loaded onto a 1% agarose gel and electrophoresis was carried out for two 
hours at 25 volts. The gel was then stained in ethidium bromide (EB) [0.5 mg/ml] for five 
minutes followed by a de-stain in distilled H20 and imaged using the GeneSnap Bioimaging 
system. 
DNA Cleavage Assay by TOP1 
 A modified DNA Cleavage Assay has been developed to study specifically the 
cleavage reaction of TOP1. TOP1 is in an enzyme that operates on a supercoiled DNA 
substrate in a catalytic fashion. This can be exploited to show that in the presence of a low-
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salt ionic environment and high ratios of TOP1 to DNA, elevated cleavages will be 
detectable on the agarose gel as the nicked-open circular (form II).  Setting up this type of 
environment will increase the processivity of TOP1 and promote elevated binding to DNA. 
Optimizing this ratio of TOP1 to DNA can allow one to run a reaction in the presence and 
absence of test drug and observe if there is a knock-down effect in form II. A reduction in 
band intensity in form II DNA is consistent with catalytic inhibition. This TOP1 cleavage 
assay allows for screening of potential CICs. In the presence of CPT, a TOP1 IFP, there will 
be an increased yield in form II DNA, as well as the appearance of a linear DNA strand 
(form III). This is owning to the fact that another TOP1 molecule can cut the opposite 
strand in a concurrent manner (as a result of no salt) having that DNA-break stabilized by 
another CPT molecule. Thus, in this assay we will see TOP1 IFPs producing linear cleavage 
complexes, when usually TOP1 cleavage complexes are single-stand breaks in vivo. 
 Cleavage reactions were carried out with 100U of TOP1 and 200 ng of supercoiled 
pHOT-1 in a 1X TG buffer containing (100 mM Tris-HCl, pH 8, 10 mM EDTA, 1 mM 
spermidine, 1% bovine serum albumin, 5% glycerol) and indicated drug in a final volume 
of 30 ul. The zero drug concentration represents a DMSO solvent control (final 
concentration of 0.1%). Reactions are prepared on ice and initiated with incubation for 30 
minutes at 37oC. Following the 30-minute incubation, reactions were stopped by the 
addition of SDS (final concentration 1%) and digested with PK [50 μg/ml] for 30 minutes at 
37oC. DNA loading dye was added (0.017 % bromophenol blue and 6.67% glycerol), and 20 
ng of DNA was then loaded onto a 1% agarose gel, which was subjected to electrophoresis 
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for 1 hour at 50 volts. EB at a final concentration of [0.5 mg/ml] was contained in both the 
gel and running buffer. The gel was briefly de-stained in distilled H2O and imaged using the 
GeneSnap Bioimaging system. 
TOP2α Decatenation Assays 
 A decatenation reaction was performed with kDNA and human TOP2α. Unless 
otherwise indicated, 200 ng of kDNA was incubated with 4U TOP2α in a TOP2 reaction 
buffer (50 mM Tris-HCl, pH 8, 150 mM NaCl, 10 mM MgCl2, 0.5 mM DTT, 300 ug/ml BSA, 20 
mM ATP) with the indicated amount of control drug or test drug. Reactions were incubated 
for 30 minutes at 37oC and terminated by the addition of adding SDS (final concentration of 
1%) and digesting with PK [50 μg/ml] for 30 minutes at 37oC. DNA loading dye was added 
(0.017 % bromophenol blue, 0.017% xylene cyanofol 6.67% glycerol) and a phenol-
choloroform extraction was performed. An equal volume of Phenol:Chloroform:Isoamyl 
(PCI) alcohol (25:24:1 w/v) was added and samples were vortexed briefly (10 seconds) 
and spun for 5 min at 13,000 RPM. The upper phase (aqueous layer) was transferred to a 
new tube and 50 ng of DNA was loaded onto a 1% agarose gel and subjected to 
electrophoresis for 20 minutes at 200 volts. EB at a final concentration of [0.5 mg/ml] was 
contained in both the gel and running buffer. The gel was briefly de-stained in distilled H2O 
and imaged using the GeneSnap Bioimaging system. 
Surface Plasmon Resonance Analysis 
 The technique of Surface Plasmon Resonance (SPR) provides a method for 
measuring and quantifying equilibrium dissociation constants (KD) in real time. The KD is 
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calculated by dividing the dissociation constant (Kd) by the association constant (Ka) [KD = 
Ka/Kd]. The method utilizes the physical properties of light reflection and electromagnetic 
wave propagation. Briefly, a light source is focused at a fixed angle with the incident light 
ray traveling through a prism until it comes into contact with the metal-coated sensor chip. 
At this point the electromagnetic wave will propagate in the direction parallel to the 
electromagnetic forces from the chip[37]. The light then makes an angle of reflection that is 
recorded by the detector after traveling back through the prism. The angle of reflection 
recorded is thus variable and dependent on what is attached to the chip.  In an SPR 
experiment, a molecule of interest (known as the ligand) is conjugated covalently on the 
topside of the chip, where the incident ray is focused on the bottom side of the chip. Next a 
buffer containing your second molecule of interest (known as the analyte) is perfused over 
the topside of the chip. If there is an interaction between the ligand and analyte then the 
angle of the light reflecting off the chip will change as the mass on top of the chip increases 
in value. The detector will record this change in angle, known as the SPR response. 
 DNA-Drug, Protein-Drug, and Ternary DNA-Drug-Protein interactions were 
performed using a Reichert SR7000 SPR refractometer (Reichert Inc., Depew, NY, USA). 
Two sensor chips were utilized in the following experiments, a DNA chip and a TOP1 chip. 
In the first set of experiments, DNA served as the ligand where a biotinylated twenty base-
pair duplexed DNA segment (Fig. 6) was immobilized to a neutravidin coated sensor slide 
(Reichert Inc., Depaw, NY, USA) at a flow rate of 41 μl/min a 1X HBS buffer (10 mM HEPES 
pH 7.4, 150 mM NaCl and 3 mM EDTA, 10% DMSO). A total of 60 ng of DNA was perfused 
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over the chip in the HBS buffer to saturate the chip. Gold(III) macrocycles (in a 10% DMSO 
solution) as analytes were perfused over the DNA chip at a set concentration of 50 nM to 
check for binding. Macrocycles that bound DNA with a significant SPR response were then 
titrated over a five-concentration range to establish a KD. After checking Drug-DNA 
interactions, TOP1 was perfused over the DNA chip as a control to check for binding to the 
biotintylated DNA. Then, a combination experiment was carried out where a solution 
containing Drug-TOP1 was perfused over the DNA chip to determine whether the drug 
blocked the binding of TOP1 to the DNA. 
 A protein chip was made with the TOP1 mutant (Y723F) serving as the ligand was 
conjugated to the sensor slide (Reichert Inc., Depew, NY, USA) via an anti-TOP1 mouse 
monoclonal antibody (TopoGEN) cross-link. The sensor slide was activated with N-
hydroxysuccinimide (NHS) and 1-(3-(dimethylamino)propyl)-3-ethylcarbodimide 
hydrochloride (EDC) in a 1:1 ratio, which serves as a cross-linker for antibody conjugation 
to sensor slide via amide chemistry. NHS and EDC were prepared as 0.5 M and 0.2 M EDC 
solutions in deionized H20 and stored at -80oC until the time of the experiment. NHS and 
EDC were mixed in a 1:1 ratio and perfused over the top of the chip. Following activation, 
an antibody solution containing 950 ng of TOP1 antibody in a sodium-acetate buffered 
solution (pH 5.4) was applied on top of the sensor chip. Next 320 ng of TOP1 enzyme was 
mixed in a solution of 0.05% Tween 20 Phosphate Buffered Saline  (PBS-T) which bound 
with high specificity to the antibody. First, gold(III) macrocycles were perfused over the 
chip to establish Drug-Protein interactions. Second, the same DNA substrate from the DNA 
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chip was perfused over the protein chip to check as a control. Third, a solution containing 
Drug-DNA (equilibrated for 5 min. at 37oC) was perfused over the chip to see if binding of 
the DNA to the protein was inhibited in the presence of the drug. 
Reichert Labview software was used for data collection and Biologic Scrubber 2 
software (Campbell, Australia) was used for curve fitting and data analysis. Experiments 
were performed with assistance from a colleague, Dr. Mike Taylor, Ph.D. (from the lab. of 
Dr. Kenneth Teter, University of Central Florida), who operated the SPR machine and 












Figure 6 – Biotinylated DNA substrate used in binding experiments 
 
          
Shown above is the biotinylated DNA substrate used in the SPR experiments. The 
oligonucleotide contains three 5’-TA-3’ dinucleotide sites (boxed in yellow) corresponding 
to the preferred TOP1 binding site. This is also the hypothesized intercalation site for 
compound 3. The DNA substrate was immobilized onto the sensor slide through 
streptavidin-biotin coupling serving as the ligand in the DNA chip. Also, the oligonucleotide 
was used as the analyte in subsequent experiments, where the DNA was perfused over the 













National Cancer Institute COMPARE Analysis: Cytotoxicity Screen against panel of 60 Cancer Cell 
Lines 
 The Developmental Therapeutics Program (DTP) at the National Cancer Institute 
(NCI,USA) provides a high-throughput screening service of potential anti-cancer agents 
against a panel of 60-human tumor cell lines. The mission was started in the early 1990s 
and, as reported by Holbeck et al. has screened over 100,000 compounds and 50,000 
natural product extracts [39, 40]. Coupled to the cytotoxicity assay, the NCI has developed a 
COMPARE algorithm available on their website (dtp.nih.gov) that provides a method to 
compare your compound of interest against the current FDA-approved anti-cancer agents 
that are included in the test. The COMPARE algorithim is subject to modification by the 
investigator, and can be adapted based on the current study. 
 The details of the cytotoxicity assay can be found on the DTP website at 
(dtp.nci.nih,gov/branches/btb/ivclsp.html). Briefly, a one-dose screen is initiated by the 
NCI for preliminary testing. Tumor cells are seeded at a set density in a 96-well plate and 
incubated at 370C in a 5% CO2 humidifier for one day. After the one day incubation, cells 
were allowed to reach exponential growth and cell density was recorded via fixation and 
staining with sulphorhodamine B and processed as the zero time point. To the rest of the 
plates, designated drugs were added at a final concentration of (1 x 10-5 M), and allowed to 
incubate for another two days. After the two-day incubation cell density was recorded and 
processed in the same manner. Growth inhibition of the tumor cells was then calculated 
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relative to the untreated cells at the zero time-point. This allows for determination of cell 
killing, and total net growth inhibition. 
 Dr. Munro performed data interpretation of the NCI-60 cytotoxicity screen and 
hiercheal cluster analysis via the COMPARE algorithim. The cluster analysis grouped 
compounds with a known mechanism of action for cell killing using GI50. Shown in (Fig. 5) 
are data from the NCI-60 screen and cluster analysis of the butyl complex (cmpd. 3), 












Chapter 3: Results 
Gold (III) Macrocycles are DNA Intercalators that bind to DNA with a strong affinity 
 Spectroscopic studies with calf thymus  (CT) DNA and gold macrocycles were 
performed by Kate Akermann prior to receiving the compounds (data not shown). The 
analysis was performed with a spectrophotometer and measured absorbance changes at 
260 nm. CT DNA was intercalated in solution with EB and a peak value was recorded. 
Various concentrations of the designated gold macrocycle were titrated into solution to 
measure displacement of the EB by the gold macrocycle. The data reveal that the gold 
macrocycle specifically displaced EB molecules and bound to CT DNA with an association 
constant (Ka) in the low micromolar range. Studies with the metal-free macrocycle and 
nickel-based macrocycle show an inability to displace EB and bind to DNA. This indicated 
that the Au3+ ion allows for a quintessential ionic interaction to take place with the DNA, 
which allows for DNA binding to occur. 
 Dr. Munro observed further conformation of DNA binding in a simple gel-shift assay 
with supercoiled pHOT1 plasmid and the propyl macrocycles. (data not shown). This shift 
was observed with the propyl gold(III) macrocycle (compound 1), but was not seen with 
the propyl metal-free macrocycle (compound 6) or the propyl nickel macrocycle 
(compound. 7). A shift occurs on the gel as a result of the change in molecular weight of 
complex that is migrating through the 1% agarose gel. 
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 The mode of interaction between the drug and DNA was determined in a DNA 
unwinding assay (Fig. 7A). As described in chapter 2, the DNA unwinding assay measures 
the various topological states of the DNA in the presence of a DNA intercalator. In the 
presence of (m-AMSA) a known DNA intercalator we see the DNA winding back up in the 
direction of Form IR (relaxed DNA) to Form I DNA (supercoiled DNA) (lanes 3-5), which is 
diagnostic for intercalation. This serves as a positive control and provides a reference for 
our test compounds. In lanes 6-8 we observe the gold(III) propyl macrocycle (compound 1) 
intercalating into the DNA and winding it up at lower concentrations as compared to (m-
AMSA). In lanes 9-14 we observe compounds 6 and 7, metal free and nickel macrocycle 
respectively; reveal no binding of DNA over the same concentration range. This gives 
further conformation that the Au3+ allows DNA intercalation to occur. 
 We examined a complete unwinding profile over a wide range titration of the butyl 
gold(III) complex (compound 3) (Fig. 7B). We detected intercalation in the nM range (lanes 
8 and 9), as a shift of topoisomers from the form IR DNA (relaxed) to the form I DNA 
(supercoiled). In this case, the intercalator winds the DNA back to take on a compact 
structure. At 5 μM we observe the drug fully winding the DNA (lane 10. The data show that 
















A) A DNA unwinding assay was performed with 200 ng pHOT-1 supercoiled DNA, 10U 
TOP1 and three propyl macrocycles containing the Au3+ cation, Ni2+ and the metal-free 
complex. The forms of DNA are denoted as I(supercoiled), IR(relaxed), II(nicked-open 
circular). Lane 1 represents the –TOP1 negative control and lane 2 is the +TOP1 positive 
control. The reactions were assembled in materials and methods (m-AMSA) was used as a 
positive control for a DNA interclator in lanes 3-5. After fully relaxing the DNA, indicated 
drug was added and further incubated for 30 minutes. The reactions were stopped with 1% 
SDS, digested with PK (50 μg/ml) and phenol:chloroform extracted and resolved on a 1% 
agarose gel for 2 hours at 25V. The gel was then stained in EB [0.5 mg/ml] for 5 minutes 
and destained in distilled water for 5 minutes. Lane 1 represents the –TOP1 control and 
lane 2 represents the +TOP1 control. Lanes 3-5 is (m-AMSA) over a three-concentration 
titration. Lanes 4-12 represents a wide range titration of compound 3. Lanes 6-8 represent 
compound 1, lanes 9-11 show compound 7 and lanes 12-14 show compound 6. All the 
macrocycles were titrated over the same concentration range [0.5-50 μM].   
 
B) A DNA unwinding assay was performed with 200 ng of pHOT-1 supercoiled DNA,10U of 
TOP1 and the lead compound, Macro_Bu_Au (compound 3) over a wide titration range in 
the same manner as described in panel A. The forms of DNA are denoted as I(supercoiled), 
IR(relaxed), II(nicked-open circular). Lane 1 represents the –TOP1 negative control and 
lane 2 is the +TOP1 positive control. Lane 3 represents the solvent control (DMSO, 0.1%). 
Lanes 4-12 represent compound 3 titrated from pM to μM. Lanes 13-15 show (m-AMSA) 










 To quantify the interaction between the DNA and macrocycles, an SPR analysis was 
conducted with the DNA chip as described in materials and methods. An SPR experiment 
was performed to monitor binding between the gold(III) macrocycles and DNA using the 
DNA chip containing the oligonucleotide (see Fig. 6). The macrocycles (serving as the 
analytes) at 50 nM were perfused over the chip in a 10% DMSO solution. The data reveal 
(Fig. 8) reveal that the butyl (compound 3) and propyl (compound 1) gold(III) macrocycles 
elicited strong SPR responses. We also see additional binding capacities in both of these 
response curves where binding levels off, followed by additional binding events.  With the 
nickel macrocycle and the metal-free macrocycle, compounds 7 and 6 respectively did not 











Figure 8 – Gold (III) macrocycles bind to DNA and elicit an SPR response 
 
An SPR binding experiment was carried out with the DNA chip as described in chapter 2. In 
this experiment the various macrocycles were perfused over the chip at 50 nM as the 
analytes. The oligonucleotide (Fig. 6) was covalently conjugated to the sensor chip as the 
ligand. A total of 100 μl of macrocycles were perfused over the chip and binding was 







 In a second SPR experiment with the DNA chip, the butyl and propyl gold(III) 
macrocycles, compounds 3 and 1 respectively were titrated over a 4 log-scale to calculate a 
KD against DNA. The results of the titration experiment with compounds 3 and 1 are shown 
below in (Fig. 9). The propyl gold(III) macrocycle (compound 1) has a KD of 2.88 μM and 
the butyl gold(III) macrocycle (compound 3) has a KD of 15.32 μM. The data thus show that 
compound 1 binds to DNA more strongly than compound 3, but within the same order of 
magnitude. Moreover, the results of Fig. 8 portray compound 3 to associate with DNA at a 
much faster rate compared to compound 1. By determining KD values, we have taken into 


























A quantitative SPR experiment was carried out in Fig. 9 utilizing the propyl and butyl 
gold(III) macrocycles (compounds 1 and 3 respectively) as analytes and DNA as the ligand. 
The experiment is carried out with the DNA described in (Fig. 6) and as described in 
materials and methods. A total aliquot of 100 μl of drug was perfused over the DNA chip at 
























 To test if the gold (III) macrocycles could bind to TOP1, an SPR experiment was 
performed with the protein chip. Catalytically inactive TOP1 (Y723F mutant) was 
conjugated to the sensor slide as described in materials and methods to serve as the ligand. 
The macrocycles were then flown over the protein as the analytes at 50 nM. The butyl 
gold(III) macrocycle (compound 3) does not bind to  the TOP1 protein (Fig. 10). The 
remaining compounds yielded the same results (data not shown). This result demonstrates 

















Catalytically inactive TOP1 mutant (Y723F) was attached to the sensor chip, serving as the 
ligand in the experiment. The butyl gold(III) macrocycle (compound) was perfused over 
the chip as the analyte at 500 nM in a DMSO solvent . The drug was perfused over the chip 






NCI-60 Cytotoxicity Assays and COMPARE Analysis Reveal Significant Anti-Tumor Potential with 
the Butyl Complex Clustering to TOP1-Targeted Agents 
 Each of the macrocycles were screened against their panel of 60 human tumor cell 
lines in a high throughput cytotoxicity assay. Compounds were first put through a one-dose 
(10 μM) concentration screen to check for gross cytotoxicity in a high throughput screen. 
Only the butyl gold(III) macrocycle (compound 3) was further titrated over a five-log scale 
to analyze cell killing over a wider concentration range. Currently, compound 3 has just 
advanced to animal tumor models in the NCI hollow fiber assays 
(http://dtp.nci.nih.gov/branches/btb/hfa.html). 
The results of the NCI-60 cytotoxicity screen and COMPARE hiercheal cluster 
analysis of the butyl gold(III) macrocycle (compound 3) is shown in (Fig. 5). The results 
portray significant anti-tumor potential with a GI50 values in the low micromolar range. The 
cluster analysis of the butyl macrocycle (compound 3) next to TOP1-targeted agents (Fig. 
5B) suggested that TOP1 might be the possible target for the macrocycles. Thus to discern 
the true mechanism of action, a series of mechanistic-based topoisomerase assays were 
performed. 
Gold (III) Macrocycles are dual Catalytic Inhibitors of TOP1 and TOP2α 
A TOP1 DNA cleavage assay was then carried out as described in materials and 
methods. All seven compounds were analyzed and the results from the lead compound, 
butyl complex (compound 3) are shown in Fig. 11. Five gold compounds (compounds 1-5) 
effectively inhibited the cleavage activity of TOP1 based on dose-dependent reduction of 
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nicked-open circular DNA (form II) in Fig. 11. The butyl complex (compound 3), which was 
the most cytotoxic in the NCI-60 screens, yielded an enzyme IC50 (concentration that 
inhibits 50% of the reaction) of 9.2 μM. In lanes 3-8 we titrate the drug over a small scale 
concentration range and observe a dose-dependent decrease in the yield of Form II DNA 
The rest of the complexes showed similar inhibitory effects over a similar concentration 
range with TOP1 being completely inhibited by 20 μM with all gold macrocycles.  
 In the presence of CPT (a specific TOP1 poison) an increase in the yield of TOP1 
cleavage products (form II DNA) as well as the appearance of a linear band (form III DNA), 
which is predicted under these experimental conditions for the following reason. The low 
salt and elevated TOP1 promote multiple TOP1 cleavages at nearby cleavage sites. This 
produces two single-strand nicks that resulted in a double stand break, all stabilized by 
CPT. A control drug active as a TOP2α IFP (m-AMSA) had no effect on the yield of form II or 
form II cleavage products (Fig. 11A, lanes 9-11). This result further confirmed the high 
specificity of (m-AMSA) towards TOP2α, and demonstrates the specificity of our TOP1 DNA 
cleavage assay. Lanes 13-14 (cropped from another gel) demonstrated the inability of 

























A) A representative TOP1 DNA cleavage assay as described in chapter 2 is shown of 
Macro_Bu_Au (compound 3). Briefly, 100U of TOP1 and 200 ng of supercoiled pHOT1 were 
incubated in a reaction buffer without salt. These conditions allow the enzyme to exhibit 
enhanced cleavage activity. In lane 1, -TOP1 control, a background level of nicked-open 
circular DNA (form II) is present as a result from the DNA purification with a predominant 
amount of supercoiled DNA (form I). In lane 2, the +TOP1 control exhibits an increased 
yield of form II, which represents the cleavage activity of the enzyme. In lanes 3-8 the butyl 
complex is titrated across a small concentration range. In lanes 9-11 with (m-AMSA) we 
observe no effect on the TOP1 cleavage reaction. In lane 12, we see CPT (TOP1 IFP) 
increase the yield of form II DNA as well as the appearance of a linear band (form III), a 
consistent result due to the experimental conditions. In lanes 13 and 14 cropped from 
another gel we see that the nickel macrocycle (cmpd. 7) and metal-free macrocycle (cmpd 
6.) do not block the catalytic function of TOP1. 
B) Graphical representation of inhibition curves for the library of gold(III) macrocycles 
against TOP1. Quantification of form II DNA (nicked-open circular) in the TOP1 DNA 
cleavage assays was performed with Genesnap Bioimaging software. Upon substracting the 
C 
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background signal from lane 1, we set the signal obtained from lane 3 as 100% catalytically 
active as our reference and divided the band intensities obtained in lanes 4-8 by the value 
obtained in lane 3 to come up with an IC50(concentration that inhibits the reaction 50%).  
C) Summary of data reporting IC50, R2 and hill coefficient values for the five gold (III) 
macrocycles from the curve fits in part B. The data analysis was performed with Kyplot and 
the function used to fit the data is F(x) = 100/(1+(10X/A)B) where F(x) is the % of NOC DNA 
(Form II), x=drug conc., A=IC50, B= hill coefficient. The IC50 represents the concentration of 
drug that results in 50% enzyme activity. The hill coefficient is a positive integer, which 
represents multiple drug binding sites in the DNA. The data is reported  as the result of one 
independent experiment per drug. The R2 values of the fits indicate the data are reliable 










TOP2α decatentation assays were carried out to determine whether the gold(III) 
macrocycles inhibit or poison this enzyme. Decatenation assays were performed in (Fig. 
12) as described in materials and methods using VP-16 as the positive control for a TOP2α 
IFP. The effect of VP-16 poisoning was measured by the appearance of a linear band 
corresponding to the TOP2-covalent cleavage complex. The propyl (cmpd. 1), dimethyl 
(cmpd 2.) and butyl (cmpd. 3) gold macrocycles titrated over a wide-range logarithmic 
scale in a kDNA decatenation is shown in (Fig. 12A). The data reveal that gold(III) 
macrocycles are TOP2α CICs. The enzyme was completely inhibited by 500 μM (Fig. 12A, 
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lane 14) as measured by the retention of the catenated form (cat.) of kDNA in the wells of 
the 1% agarose gel. The TOP2α decatenation reaction was unaffected by the metal free and 
nickel macrocycle, compounds 6 and 7 respectively (lanes 6 and 7, Fig. 12B), thus 



































TOP2α reactions were carried out with 200 ng of kDNA and 4U of TOP2α with compounds 
1, 2, 3 as described in materials and methods. Reactions were incubated for 30 minutes at 
37 OC, stopped with 1% SDS and digested with PK (50 μg/ml) for another 30 minutes at 37 
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OC . The reaction products were resolved on a 1% agarose gel containing EB in the gel and 
running buffer at a concentration of 0.5 mg/ml.The different forms of DNA are denoted as: 
cat. (catenated DNA), Lin. (linear DNA), NOC (nicked-open circular DNA) and CCC 
(covalently-closed circular DNA). Lane 1 represents kDNA in its catenated form, unable to 
travel through the 1% agarose gel. In lane 2, the TOP2α decatenation products are shown 
producing the NOC and CCC forms of DNA. Lane 3 represents the DMSO (solvent control) at 
a final concentration of 0.1%. In lane 4, kDNA is linearized by the restriction enzyme Xho1 
resulting in a single linear band. Lane 5 is a control for a TOP2α IFP, VP-16 at a final 
concentration of 50 μM. In lanes 6-14 we observe a wide range titration of the indicated 
gold(III) macrocycle.  
B) TOP2α reactions were carried out with 200 ng of kDNA and 4U of TOP2α with 
compounds 1, 2, 3 as described in materials and methods. Reactions were incubated for 30 
minutes at 37 OC, stopped with 1% SDS and digested with PK (50 μg/ml) for another 30 
minutes at 37 OC . The reaction products were resolved on a 1% agarose gel containing EB 
in the gel and running buffer at a concentration of 0.5 mg/ml.The different forms of DNA 
are denoted as: cat. (catenated DNA), Lin. (linear DNA), NOC (nicked-open circular DNA) 
and CCC (covalently-closed circular DNA). Lane 1 represents kDNA in its catenated form, 
unable to travel through the 1% agarose gel. In lane 2, the TOP2α decatenation products 
are shown producing the NOC and CCC forms of DNA. Lane 3 represents the DMSO (solvent 
control) at a final concentration of 0.1%. In lane 4, kDNA is linearized by the restriction 
enzyme Xho1 resulting in a single linear band. Lane 5 is VP-16, serving as a control for a 
TOP2 IFP at a final concentration of 50 μM. In lanes 6 and 7 we observe the metal free and 











DNA Intercalation is the mode of action by which Gold (III) Macrocycles prevent TOP1 from 
forming a non-covalent complex with DNA 
 SPR combination experiments were performed by perfusing the TOP1 mutant 
(Y723F) over the DNA chip in the absence or presence of the butyl gold (III) marcocycle 
(compound 3). Compound 3 appears to bind DNA in a step wise process (Fig. 13A). In 
addition, the TOP1 mutant (Y723F) also binds DNA in the absence of the drug (Fig. 13B). 
When the TOP1-compound 3 solution (50 nM) as the analyte was tested for binding, nonr 
was observed (Fig. 13B). This reveals that the intercalative gold compound blocks TOP1 
from binding to the DNA. A binding event was observed when the TOP1-metal free complex 
(compound) as the analyte was perfused over the DNA chip, demonstrating that the metal-










Figure 13- Butyl gold(III) marocycle prevents TOP1 from binding to DNA 
 
A) An SPR experiment was performed with the DNA chip (sequence shown in Fig. 6) in the 
presence of the butyl gold(III) macrocycle (compound 3). The experiment was conducted 
by perfusing compound 3 at 50 nM in 10% DMSO over the DNA chip.with cmpd. 3 at 50 nM 
in a 10% DMSO solution. A total of 100 μl aliquot of drug was perfused over the DNA chip 
as the analyte. 
B) An SPR experiment was performed with the TOP1 mutant (Y723F), to strictly measure 
the non-covalent complex formed between TOP1 and DNA. An aliquot of 100 μl containing 
150 ng of TOP1 was flown over the DNA to check for binding. Then in a second experiment, 
TOP1 (150 ng) was combined with the butyl gold(III) macrocycle at 50 nM and perfused 





 TOP1/DNA interactions were examined in the presence or absence of gold(III) 
macrocycles by SPR. The SPR response of DNA perfused as the analyte over TOP1 is shown 
in (Fig. 14). In combination experiments, the butyl gold(III) macrocycle (compound 3) was 
allowed to equilibrate with the DNA for 5 minutes at 37oC. The presence of the gold 
macrocycle inhibited binding of the DNA to TOP1 (Fig. 14). The DNA incubated in the 
presence of the metal-free macrocycle (compound 6) retained the ability of the DNA to bind 
to TOP1 (data not shown). By conducting these experiments in reverse manner we confirm 
our mechanism of action for catalytic inhibition of TOP1. By intercalating into the DNA and 
not binding the to the enzyme we demonstrate the ability of the gold(III) macrocycle to 











Figure 14 – Butyl gold (III) macrocycle prevents DNA from binding TOP1 
 
 
A competition SPR experiment was carried with the TOP1 chip. DNA alone as the sole 
analyte (oligonucleotide described in Fig. 6) was perfused over the TOP1 chip. The DNA 
was then pre-incubated with the butyl gold(III) macrocycle (compound 3) at 50 nM for 5 






Butyl Gold (III) Macrocycle prevents formation of TOP1-Covalent Cleavage Complex by CPT 
 A TOP1 DNA Cleavage Assay was performed with the butyl gold (III) macrocycle 
(compound 3) in the presence of CPT (Fig. 15). The results in (Fig. 11) demonstrate that 
compound 3 is a TOP1 CIC that accomplishes its mechanism through an intercalative mode. 
Since the inhibition of TOP1 takes place at the step of DNA binding to protein, we asked the 
question if cmpd. 3 could effectively inhibit the CPT-induced TOP1 cleavage complex. In the 
presence of CPT [100 μM] we measured formation linear band (form III) (Fig. 15, lanes 6-
8) with increasing enzyme input. Due to low ionic conditions (no salt in the reaction buffer) 
the enzyme is highly processive, which enchances TOP1/DNA binding and promotes 
contiguous cutting of the DNA at nearby sites or opposite stands. This leads to formation of 
linear (form III) DNA. Intercalation of compound 3 effectively blocks this event. By 
inhibiting formation of the TOP1-CPT induced cleavage complex we confirm that 
compound 3 and CPT are both localized to the enzyme’s cut-site. Although, we cannot rule 
out the fact that intercalation sites distal to the enzyme-cut site can also result in the 









A TOP1 DNA cleavage assay was carried with out with supercoiled 200 ng of pHOT1 DNA 
and indicated amounts of TOP1 as described in materials and methods: Form I represents 
supercoiled DNA, form IR is relaxed DNA, form II is nicked-open circular DNA and form III 
represents linear DNA. Lane 1 represents mostly form I DNA in the absence of enzyme or 
drug to show the background level of form II DNA as a result from the DNA purification. 
The enzyme is then titrated in lanes 2-4 to show the increase in form II. In the presence of 
CPT [100μM], lanes 5-7 we see a dose dependent increase in form III. In lanes 8-10, the 




Chapter 4: Discussion 
 In this work, we have identified the molecular basis by which gold(III) macrocycles 
act as TOP1 and TOP2α catalytic inhibitors (CICs). DNA intercalation is the primary 
mechanism by which the gold (III) macrocycles inhibit these enzymes. Most likely, the 
inhibition is accomplished by distorting the geometry of the enzyme cut-site, impairing the 
ability of the enzyme to bind to its substrate and perform its catalytic reaction.  At the 
moment, the sequence-specificity of the gold(III) macrocycles is being determined via 
molecular simulations  
Preliminary results from the simulations with the butyl gold(III) macrocycle 
(compound 3) (Fig. 16) suggests that the complex targets a “TA” di-nucleotide via the 
major groove, corresponding to the cut-site for TOP1[13]. Viewed in Fig. 16A is the DNA 
unbound and and in complex with compound 3. The molecular surface representation 
reveals cmpd. 3 to intercalate into the DNA as predicted, and fit the contour of the major 
groove of DNA. This alters the shape of the DNA and adds steric bulk to the DNA, which 
distorts the substrate for the enzyme. The molecular recognition unit of the enzyme then 
fails to recognize its sequence-specific cut-site. The sequence was determined via 
thermodynamic values obtained in the simulation that rendered the “TA” intercalation site 
in the lowest energy conformation, translating to the most stable complex. A co-
crystallization experiment with DNA and compound 3 could confirm this result. Nucleotide 
specificity may play an important role in regards to cell cytotoxicity. 
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In addition to base-pair specificity, the simulation work also provides a valid reason 
why the gold (III) macrocycles bind to DNA (and not the gold-free macrocycle, compound 
6). The simulation data reveals a non-traditional interaction seen with the Au3+ and the 
carbonyl oxygen on the thymine residue (Fig 16B). The 3.1Å bond formed resembles that 
of a hydrogen bond, where in this case the Au3+ accepts an electron pair donated by the 
carbonyl oxygen. Originally it was hypothesized that the Au3+cation would interact with 
negative charges on the sugar-phosphate backbone, however the simulations suggests 
otherwise. If the gold cation is left out of the macrocycle; the π-π interactions between drug 
and bases of DNA are not sufficient enough to form a stable complex. Based on the 
simulation data we would conclude the two main driving forces for compound 3 binding to 
DNA is, an Au3+--(O=C) 3.1 Å bond in conjunction with stable π-π interactions of the 









Figure 16 – Molecular simulation of butyl gold(III) macrocycle intercalated into DNA 
(produced by Dr. Munro) 
 
*This figure was produced by Dr. Munro in his molecular simulation studies 
A) A molecular surface representation of the DNA in the absence and presence of the butyl 
gold(III) macrocycle (compound 3). The simulation reveals cmpd. 3 localized to a “TA” di-
nucleotide site. When compound 3 is intercalated into the DNA, we observe local 
unwinding of the helix, as well as a change in the geometry of the DNA at the intercalation 
site. This simulation provides a molecular basis for why TOP1 and TOP2α cannot bind and 
cut DNA. 
B) The specific interactions between compiund 3 and the DNA are shown with DNA 
represented in stick notation, and compound 3 in ball and stick notation. The critical 
interaction between the Au3+ and carbonyl of the T10 residue is shown, which allows for 
compound 3 to remain in a tight association with the DNA. The butyl gold(III) macrocycle 
also interacts with T10 and A11 through π-π stacking with the bases that further stabilizes 




An intercalation event at the enzyme cut-site, would classify the gold(III) 
macrocycle as a competitive inhibitor as the drug is competing with the enzyme for the 
same DNA sequence. It is possible that this is the case with some of the macrocycles, but an 
intercalation event at a di-nucelotide sequence distant from the cut-site could also inhibit 
the enzyme, which would be referred to as non-competitive inhibition. It is known that 
intercalation of the DNA produces local unwinding of the helix[22, 38, 39]. Given sufficient 
intercalation events it is possible to unwind the DNA enough to form a structure that 
sterically hinders enzyme access to the cleavage site. This is plausible and consistent with 
the DNA unwinding data (Fig. 7) demonstrates the gold (III) macrocycles unwind the DNA 
in a strong manner. Further simulation and crystallization experiments should confirm 
which intercalation mechanism is predominant. 
Since the butyl gold(III) macrocycle (compound 3) forms a seven-membered ring in 
the linker region (denoted X in Fig. 4), the resulting confirmation causes the ring to bridge 
above and below the plane. All of the other macrocycles form a six-membered ring with no 
bridge; this slight difference in structure could be the reason as to why the butyl 
macrocycle is most cytotoxic in cells. The in vitro topoisomerase assays reveal compound 3 
to act as a catalytic inhibitor in the same concentration range as compounds 1-5 (Figs. 11 
and 12). This seven-membered ring formed in the butyl complex cannot be ignored, as it 
might have something to do with the enhanced cytotoxicity in the NCI-60 screen. The 
bridge created above and below the plane might fit the major groove of the DNA better 
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than the other macrocycles. Additionally it might also inhibit other essential DNA-binding 
enzymes that we are not aware of. 
In the SPR experiments with the DNA bound chip in (Fig. 9), we observe a stronger 
binding affinity with the propyl gold(III) macrocycle (compound 1) than with the butyl 
gold(III) macrocycle (compound 3) yielding KD values of 15.32 μM for compound 3 and 
2.88 μM for compound 1. More interesting is the way the SPR response is seen qualitatively 
in (Fig. 8). With both compounds 1 and 3 a certain amount of drug binds, followed by a 
period of no detecable binding,  then followed by further increase in the response curve 
(representing additional binding). This result is suggests multiple binding events on the 
target. The DNA helix unwinds upon a first intercalation, allowing additional molecules of 
drug to bind to distant sites. In vivo this could have a cooperativity effect where the binding 
of one drug influences additional binding downstream or upstream from the first 
intercalation site. The possibility of multiple binding and enhanced cooperativity is simply 
a speculation at this point, but working this out experimentally could lead to a valuable 
advancement in the knowledge of how these drugs work in vivo.  
Described above are some possible reasons as to why the butyl gold(III) macrocycle 
(compound 3) is most cytotoxic in cells. Since the TOP1 assays do not reveal significant 
differences in IC50 values (Fig. 11), there must be a reason as to why there is a variable 
difference in cytotoxicity amongst the macrocycles within the NCI-60 screen. The 
mechanism by which the gold(III) macrocycles as a family of compounds that intercalate 
into DNA and inhibit TOP1 and TOP2α has been described. The main goals now lie in the 
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area of crystal structure and confirmation of the molecular mechanism in vivo. It is known 
that many cellular processes work differently in vitro than in vivo. Furthermore, there is a 
pressing need to study the macrocycles purely in vivo to see if there are other molecular 
targets. 
 The Au3+ ion does not readily dissociate out of the macrocyclic complex. Carrying an 
overall positive charge with a planar and hydrophobic backbone makes the drug a good 
candidate for traversing the cell membrane. However, this has not been studied 
experimentally and needs further evaluation.  Certain drugs are known to enter the cell 
non-specifically via the transmembrane protein transporters[40-43].  This is the primary 
route of drug resistance, because cancer cells can mutate protein transporters that are 
unable to carry the drug. This is important because it is known that many drugs are active 
in vitro, but then the cell acts in such a way to metabolize the drug and render it inactive. 
This effect is seen with CPT, as the molecule can become inactivated in the “open-ring” 
lactone form. Further studies with cells should be carried out to assess the 
pharmacokinetics and dynamics of drug-uptake into cells. 
 Transitioning this compound into clinics will take time, but has a real potential to 
treat cancer. Most cancer drugs are genotoxic, resulting in massive DNA damage.  Coupled 
to the genotoxic events is collateral damage to healthy cells such as cardiac cells, which is 
the case when patients are treated with doxorubucin, a TOP2α IFP[5]. A treatment strategy 
employed to reduce collateral treatment has been the synergism of doxorubucin with ICRF 
compounds[16]. The principle here is that some of the TOP2α molecules become locked in 
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the “closed-clamp” confirmation as the result of ICRF mediated catalytic inhibition. This 
prevents some TOP2α molecules from becoming lethal in the cell by forming DNA DSBs. 
This same strategy can be employed by treating patients with the gold macrocycle coupled 
with CPT, the TOP1 IFP.  
 Additionally, treating patients with the gold macrocycle independent of an IFP can 
result in cell killing with a less genotoxcicity as compared to other cancer 
chemotherapeutics. Treatment with the CIC can effectively inhibit TOP1 and TOP2α, which 
are both required for cell proliferation. By shutting off these essential enzymes, the cell will 
acquire a build up of topologically constrained DNA, and the accumulation of this DNA will 
signal for cell death. 
 In conclusion, a series of macrocyclic gold (III) complexes have been synthesized 
and studied extensively in vitro. The data reveal the complexes to have anti-tumor potential 
with a specific molecular mechanism. There is a desperate need for new anti-cancer agents 
in the clinic, and this class of compounds has serious potential. They should be studied 
extensively in vivo with animal models to evaluate the compounds in a setting similar to the 
human cancer patient. Moving to an animal model marks the next step to incorporating 
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